PT-141 vs Semax
Side-by-side comparison of PT-141, Semax — mechanism, dosing, half-life, side effects, and research status.
| Attribute | PT-141 PT-141 (Bremelanotide) Recovery | Semax Semax (Heptapeptide ACTH Analogue) Cognitive |
|---|---|---|
| Basics | ||
| Molecular type | Melanocortin Receptor Agonist | ACTH-Derived Neuropeptide |
| Amino acids | 7 | 7 |
| Molecular weight | 1,025.2 Da | 813.9 Da |
| Half-life | ~2.7 hours | ~minutes (nasal); longer CNS retention |
| Route(s) | Subcutaneous auto-injector | Intranasal, Subcutaneous |
| Mechanism & Research | ||
| Primary mechanism | PT-141 activates melanocortin receptors in the central nervous system — particularly MC3R and MC4R in the hypothalamus and limbic regions. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally through va… | Semax's primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) — a neurotrophin critical for neuronal survival, synaptic plasticity, and neurogenesis. In animal models, Semax increases BDNF m… |
| Research status | FDA Approved (Vyleesi) | Research Compound |
| Evidence summary | PT-141 (Bremelanotide) was FDA-approved in 2019 based on two Phase 3 trials in premenopausal women with HSDD. Research in men demonstrates pro-erectile effects and is ongoing. | Semax has been investigated in Russian clinical research since the 1980s. It has been approved in Russia as a drug for stroke, TBI, and cognitive decline. Western research interest has grown, but large RCTs meeting curre… |
| Protocol & Dosing | ||
| Typical dose | 1.75 mg (FDA-approved dose) | 200–600 mcg/day (intranasal) |
| Frequency | As needed (max 1x per 24 hours) | 1–2x daily |
| Duration | As needed | 2–4 weeks cycles |
| Timing | 45 minutes before anticipated sexual activity | Morning (or morning + midday); avoid evening to prevent sleep disruption |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | KPV, Semax | Selank, Dihexa, P21 |
| Full profile | Read full PT-141 profile → | Read full Semax profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.